California, United States of America
The following excerpt is from In re Cipro Cases, 187 Cal.Rptr.3d 632, 348 P.3d 845, 61 Cal.4th 116 (Cal. 2015):
We also observe that the outlined prima facie showing will suffice, without more, to raise a presumption of the patentee's market power. Proving that a restraint has anticompetitive effects often requires the plaintiff to delineate a relevant market and show that the defendant plays enough of a role in that market to impair competition significantly, i.e., has market power. (Roth v. Rhodes, supra, 25 Cal.App.4th at p. 542, 30 Cal.Rptr.2d 706.) Here, proof of a sufficiently large payment is a surrogate: the size of the payment from a branded drug manufacturer to a prospective generic is itself a strong indicator of powernamely, the power to charge prices higher than the competitive level.
[61 Cal.4th 158]
The above passage should not be considered legal advice. Reliable answers to complex legal questions require comprehensive research memos. To learn more visit www.alexi.com.